Differential pathogenesis of closely related 2018 Nigerian outbreak clade III Lassa virus isolates.
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
28
05
2021
accepted:
23
09
2021
revised:
21
10
2021
pubmed:
12
10
2021
medline:
27
11
2021
entrez:
11
10
2021
Statut:
epublish
Résumé
Nigeria continues to experience ever increasing annual outbreaks of Lassa fever (LF). The World Health Organization has recently declared Lassa virus (LASV) as a priority pathogen for accelerated research leading to a renewed international effort to develop relevant animal models of disease and effective countermeasures to reduce LF morbidity and mortality in endemic West African countries. A limiting factor in evaluating medical countermeasures against LF is a lack of well characterized animal models outside of those based on infection with LASV strain Josiah originating form Sierra Leone, circa 1976. Here we genetically characterize five recent LASV isolates collected from the 2018 outbreak in Nigeria. Three isolates were further evaluated in vivo and despite being closely related and from the same spatial / geographic region of Nigeria, only one of the three isolates proved lethal in strain 13 guinea pigs and non-human primates (NHP). Additionally, this isolate exhibited atypical pathogenesis characteristics in the NHP model, most notably respiratory failure, not commonly described in hemorrhagic cases of LF. These results suggest that there is considerable phenotypic heterogeneity in LASV infections in Nigeria, which leads to a multitude of pathogenesis characteristics that could account for differences between subclinical and lethal LF infections. Most importantly, the development of disease models using currently circulating LASV strains in West Africa are critical for the evaluation of potential vaccines and medical countermeasures.
Identifiants
pubmed: 34634087
doi: 10.1371/journal.ppat.1009966
pii: PPATHOGENS-D-21-01127
pmc: PMC8530337
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1009966Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Pan Afr Med J. 2019 Oct 06;34:76
pubmed: 31819792
Med Microbiol Immunol. 1986;175(2-3):153-5
pubmed: 3724661
Antiviral Res. 2014 Dec;112:59-79
pubmed: 25448088
PLoS Comput Biol. 2019 Apr 8;15(4):e1006650
pubmed: 30958812
J Virol. 2000 Aug;74(15):6992-7004
pubmed: 10888638
Nucleic Acids Res. 2011 May;39(9):e57
pubmed: 21306991
BMJ. 1995 Sep 30;311(7009):857-9
pubmed: 7580496
Emerg Infect Dis. 2019 Jun;25(6):1066-1074
pubmed: 31107222
Infect Dis Poverty. 2018 Apr 28;7(1):37
pubmed: 29703243
Nat Methods. 2015 Jan;12(1):59-60
pubmed: 25402007
Drug Des Devel Ther. 2018 Aug 14;12:2519-2527
pubmed: 30147299
Cell. 2015 Aug 13;162(4):738-50
pubmed: 26276630
Am J Trop Med Hyg. 1970 Jul;19(4):670-6
pubmed: 4246571
J Virol. 2009 Jun;83(11):5890-903
pubmed: 19297492
NPJ Vaccines. 2018 Mar 20;3:11
pubmed: 29581897
J Vector Borne Dis. 2007 Mar;44(1):1-11
pubmed: 17378212
PLoS Negl Trop Dis. 2021 Mar 8;15(3):e0009169
pubmed: 33684118
Microorganisms. 2021 Apr 07;9(4):
pubmed: 33917071
Genome Biol. 2004;5(2):R12
pubmed: 14759262
PLoS Pathog. 2013;9(4):e1003212
pubmed: 23592977
Syst Biol. 2012 Jan;61(1):170-3
pubmed: 21963610
PLoS Biol. 2006 May;4(5):e88
pubmed: 16683862
Curr Top Microbiol Immunol. 2021 Apr 17;:
pubmed: 33861373
Antiviral Res. 2008 Apr;78(1):79-90
pubmed: 18036672
Virology. 2020 Jun;545:10-15
pubmed: 32174454
Curr Opin Virol. 2019 Aug;37:77-83
pubmed: 31323506
Mol Biol Evol. 2018 Dec 1;35(12):3041-3043
pubmed: 30351396
Science. 1974 Jul 19;185(4147):263-5
pubmed: 4833828
J Comput Biol. 2012 May;19(5):455-77
pubmed: 22506599
J Infect Dis. 2013 Apr 15;207(8):1316-27
pubmed: 23303805
Pathogens. 2020 Mar 06;9(3):
pubmed: 32155851
Nat Commun. 2016 Apr 15;7:11307
pubmed: 27079541
Curr Opin Virol. 2019 Aug;37:118-122
pubmed: 31479989